In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

After establishing Venclexta as a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), AbbVie and Roche were hoping to demonstrate the med's promise in a subset of multiple myeloma. But that effort just hit a setback.